La catena delle opzioni mostra i dati chiave delle opzioni azionarie di SeaStar Medical Holding a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per SeaStar Medical Holding..

SeaStar Medical Holding (NASDAQ:ICU) Azioni, Catena delle Opzioni

SeaStar Medical Holding

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

SeaStar Medical Holding Corporation - Common Stock

SeaStar Medical Holding Corp

SeaStar Medical Holding Corporation - Warrant

ICU Medical Inc

Goldman Sachs maintains Trinity Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRN#NYSE">TRN</a>) with a Neutral and lowers the price target from $36 to $31.

News

Price Target

Analyst Ratings

Goldman Sachs Maintains Neutral on Trinity Indus, Lowers Price Target to $31

UBS analyst Peter Grom maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and lowers the price target from $176 to $154.

UBS Maintains Neutral on Clorox, Lowers Price Target to $154

<a href="https://www.youtube.com/watch?v=LepQacb-5Sg">https://www.youtube.com/watch?v=LepQacb-5Sg</a>
&nbsp;

Macro Economic Events

Politics

Global

Economics

General

President Trump Says He And Italy's Meloni Talked About Trade; Italy's Meloni Says Italy Will Have To Increase LNG Imports, Want To Work Together On Nuclear

Stargate is considering a <a target="_blank" href="https://www.benzinga.com/topic/stargate" rel="noreferrer noopener">future investment in</a> the U.K. to build the global infrastructure needed to support advanced artificial intelligence models.
Sir Keir Starmer&#8217;s government recently announced plans to boost investment in its growing AI industry, including developers&#8217; access to energy, the Financial Times <a target="_blank" href="https://www.ft.com/content/435f0142-8bc1-43dd-9648-d7f05de1dee6" rel="noreferrer noopener">reported</a>, citing unnamed sources familiar with the matter.
The OpenAI and SoftBank (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>)- backed AI infrastructure joint venture is raising $100 billion to invest in AI infrastructure projects.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/03/44327422/softbank-to-build-676-million-ai-data-center-in-japan-linked-to-openai-partnership" rel="noreferrer noopener">SoftBank To Build $676 Million AI Data Center In Japan, Linked To OpenAI Partnership</a>
The figure could reach $500 billion over the next four years. Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) will supply 64,000 AI chips for the <a target="_blank" href="https://www.benzinga.com/25/03/44188361/nvidia-powers-openai-and-oracles-100-billion-stargate-first-ai-data-center-set-to-launch-in-texas" rel="noreferrer noopener">Stargate data center</a> in Texas. OpenAI tapped Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) to supervise the supercomputer being built in the Abilene data center.
Investment in the U.K. has been considered part of a future international expansion despite the focus on the U.S.
U.K.&#8217;s plans to boost data centers&#8217; access to electricity have stimulated the project&#8217;s interest, the Financial Times reported, citing unnamed sources familiar with the matter.&nbsp;
OpenAI said the U.K. was one of its key overseas markets.
Lately, OpenAI has been lobbying European governments to relax regulations and invest in data center infrastructure.
Last Wednesday, the European Commission announced its plan to invest more in AI data centers, including regulatory relaxations.
However, the project&#8217;s ambition remains vulnerable to President Donald Trump&#8217;s new tariff policies.
Trump&#8217;s 145% tariff on China alone could translate into over $11 billion surge in annual costs for U.S. data centre developers, Financial Times cited Altana.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43139410/softbanks-role-in-500-billion-stargate-ai-venture-seen-as-major-growth-driver-analyst-says" target="_blank" rel="noreferrer noopener">SoftBank&#8217;s Role in $500 Billion Stargate AI Venture Seen as Major Growth Driver, Analyst Says</a></li>
</ul>
Photo by AKOBCHUK via Shuttesrtock

Tech

Media

NVDA

ORCL

SFTBF

SFTBY

OpenAI And SoftBank's Stargate Considers Major UK Investment To Fuel AI Growth

Goldman Sachs analyst Chris Merwin maintains Sprout Social (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>) with a Neutral and lowers the price target from $29 to $23.

Goldman Sachs Maintains Neutral on Sprout Social, Lowers Price Target to $23

Goldman Sachs analyst Adam Hotchkiss maintains Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) with a Buy and lowers the price target from $13 to $10.

SMWB

Goldman Sachs Maintains Buy on Similarweb, Lowers Price Target to $10

UBS analyst Doug Harter maintains Ares Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>) with a Neutral and lowers the price target from $22 to $21.

ARCC

UBS Maintains Neutral on Ares Capital, Lowers Price Target to $21

Goldman Sachs analyst Paul Choi maintains Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) with a Neutral and lowers the price target from $14 to $12.

RGNX

Goldman Sachs Maintains Neutral on Regenxbio, Lowers Price Target to $12

WIIM

Trump Media & Technology Group shares are trading higher Thursday after the company sent a complaint to federal regulators, citing potential market manipulation involving its stock.

Goldman Sachs analyst Paul Choi maintains Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) with a Neutral and lowers the price target from $12 to $10.

PHAT

Goldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Lowers Price Target to $10

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) may be setting up for a breakout moment, with Felix Jauvin dubbing it the &#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44869153/unrealized-bitcoin-losses-hit-all-time-high-glassnode-says-bear-market-signs">cleanest trade after the trade</a>."
What Happened: In an <a href="https://x.com/fejau_inc/status/1912576594083971147">article</a> on April 17 on X, &#8216;Forward Guidance&#8217; podcast host Jauvin said that he sees investors reducing risk and offloading positions. 
Jauvin argues that Bitcoin is positioned to benefit from a global capital rotation unlike anything seen before in its history since it has been driven by three key factors: 
<ul>
<li>Investor appetite for high-beta risk assets</li>
<li>Its correlation with gold</li>
<li>Global liquidity </li>
</ul>
With the dollar weakening, U.S. equities underperforming global peers and gold hitting all-time highs, signs are building for a shift away from domestic markets and into borderless assets like Bitcoin.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44869153/unrealized-bitcoin-losses-hit-all-time-high-glassnode-says-bear-market-signs">Unrealized Bitcoin Losses Hit All-Time High, Glassnode Says: Bear Market Signs?</a>
Why It Matters: Jauvin sees Bitcoin as uniquely positioned offering global liquidity exposure without geopolitical baggage. 
Unlike U.S. tech stocks or foreign equities vulnerable to tariffs, political risk, or trade wars, Bitcoin is non-sovereign and censorship resistant.
While the current environment is marked by deleveraging and volatility, the &#8220;trade after the trade&#8221; is Bitcoin. 
Gold's current strength validates the shift in regime, and Bitcoin is likely to follow once the overhang of &#8220;degrossing&#8221; clears.
For a risk-seeking macro trader, Bitcoin offers asymmetric upside as a high-beta global liquidity asset that doesn't rely on the fortunes of any one country.
"You can't tariff Bitcoin," he notes, framing it as a macro hedge and clean play on global liquidity, especially as the rest of the world leans into fiscal expansion.
In this evolving macro environment, Fejau believes Bitcoin could finally decouple from U.S. equities and resume its trajectory as the "fastest horse"—a term famously used by Paul Tudor Jones to describe BTC's potential in past cycles. 
"This market regime is what Bitcoin was built for," he concludes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44863580/bitcoin-stuck-below-85000-bull-run-shakeout-or-bearish-downtrend">Bitcoin Stuck Below $85,000: Bull Run Shakeout Or Bearish Downtrend?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Is the 'Cleanest Trade' Since 'You Can't Tariff Bitcoin,' Expert Says

Goldman Sachs analyst Matthew Sykes maintains NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) with a Buy and lowers the price target from $17 to $15.

Goldman Sachs Maintains Buy on NeoGenomics, Lowers Price Target to $15

SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) announced a $2 billion extension of its Loan Platform Business agreement for personal loans with funds managed by affiliates of Fortress Investment Group ("Fortress"). This extension builds on the original $2 billion Loan Platform Business agreement between SoFi and Fortress announced in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sofi.com%2Fpress%2Fsofi-expands-loan-platform-business-2-billion-agreement-fortress-investment-group%2F&amp;esheet=54240011&amp;newsitemid=20250417276382&amp;lan=en-US&amp;anchor=October+2024&amp;index=1&amp;md5=23af581259088742ab7a743ee9c1720e">October 2024</a>.
SoFi also signed a two-year agreement to originate an additional $1.2 billion in loans, with technology powered by a joint venture between Fortress and Edge Focus.
The total commitment provided by Fortress for SoFi's Loan Platform Business has now reached over $5 billion.

SOFI

SoFi Technologies Announces $2B Extension Of Loan Platform Business Agreement For Personal Loans With Funds Managed By Affiliates Of Fortress Investment Group

Goldman Sachs analyst Matthew Sykes maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Buy and lowers the price target from $18 to $14.

MYGN

Goldman Sachs Maintains Buy on Myriad Genetics, Lowers Price Target to $14

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares are trading lower by 3.3% to $101.09 during Thursday&#8217;s session, deepening its recent slide.
What To Know: The U.S. government <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44868970/nvidia-amd-take-a-17-billion-hit-in-the-ai-arms-race-while-broadcom-remains-shielded-says-analyst">imposed new licensing rules</a> restricting sales of Nvidia's H20 and AMD's MI308 chips to China, Hong Kong, Macau and several other countries.
In response, Nvidia announced a <a href="https://www.benzinga.com/markets/25/04/44858727/jensen-huang-in-china-for-talks-as-us-tightens-nvidia-chip-restrictions-report">$5.5 billion inventory charge</a>, signaling it may be unable to ship these chips to key customers like Alibaba and Tencent. 
Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) this week meanwhile reported an $800 million charge, with estimated full-year revenue losses of up to $1.8 billion. JPMorgan analyst Harlan Sur projects these restrictions could reduce both companies&#8217; earnings <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44868970/nvidia-amd-take-a-17-billion-hit-in-the-ai-arms-race-while-broadcom-remains-shielded-says-analyst">by 8%–10% in 2025</a>.
Nvidia CEO Jensen Huang is also in Beijing Wednesday <a href="https://www.benzinga.com/markets/25/04/44858727/jensen-huang-in-china-for-talks-as-us-tightens-nvidia-chip-restrictions-report">meeting with Chinese trade officials</a>, emphasizing the company's desire to maintain ties with the Chinese market. While AI demand in China remains strong, domestic firms are now expected to accelerate adoption of homegrown alternatives like Huawei's Ascend chips.
Though <a href="https://www.benzinga.com/markets/25/04/44858727/jensen-huang-in-china-for-talks-as-us-tightens-nvidia-chip-restrictions-report">analysts</a> like Bank of America's Vivek Arya call the situation "manageable," Nvidia shares have dropped roughly 15% in the past month, as growing regulatory pressure casts a shadow over U.S. chipmakers' outlook.
Read Also: <a href="https://www.benzinga.com/etfs/sector-etfs/25/04/44868472/pillar-of-americas-cyber-security-lost-funding-temporarily-what-investors-should-know-about-cve-">Pillar Of America&#8217;s Cyber Security Lost Funding Temporarily: What Investors Should Know About CVE Program, Funding Extension</a>
<h2 class="wp-block-heading">How To Buy NVDA Stock</h2>
By now you're likely curious about how to participate in the market for NVIDIA &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of NVIDIA, which is trading at $100.25 as of publishing time, $100 would buy you 1.0 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NVDA has a 52-week high of $153.13 and a 52-week low of $75.61.

What's Going On With Nvidia Stock?

Goldman Sachs analyst Andrea Tan maintains Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) with a Buy and lowers the price target from $18 to $16.

IOVA

Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $16

Goldman Sachs analyst Paul Choi maintains Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) with a Buy and lowers the price target from $8 to $7.

GOSS

Goldman Sachs Maintains Buy on Gossamer Bio, Lowers Price Target to $7

UBS analyst Timothy Arcuri maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and lowers the price target from $175 to $155.

UBS Maintains Buy on Advanced Micro Devices, Lowers Price Target to $155

Goldman Sachs analyst Paul Choi maintains Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Neutral and lowers the price target from $4 to $3.

ESPR

Goldman Sachs Maintains Neutral on Esperion Therapeutics, Lowers Price Target to $3

UBS analyst Thomas Wadewitz maintains United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) with a Neutral and raises the price target from $59 to $67.

UBS Maintains Neutral on United Airlines Holdings, Raises Price Target to $67

Press Releases

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

FDA Approves Feasibility Study with SeaStar Medical's Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

SeaStar Medical Adds Fifth Hospital Customer for QUELIMMUNE

SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market

SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market

NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award

Health Care

SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

Earnings

SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

Comments

SeaStar Medical Holding

SeaStar Medical Holding (ICU) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO